Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b

Journal of the Neurological Sciences

Volumn 222, Issue 1-2, 2004, Pages 65-73

  Ochi, Hirofumi ^a   Feng Jun, Mei ^a   Osoegawa, Manabu ^a   Minohara, Motozumi ^a   Murai, Hiroyuki ^a   Taniwaki, Takayuki ^a   Kira, Jun Ichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

IFN ; IL 13; IL 4; Interferon beta; Multiple sclerosis; Opticospinal MS; Th1; Th2

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ETHNIC GROUP; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNE SYSTEM; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RELAPSE; T LYMPHOCYTE; TH2 CELL; TIME; UPREGULATION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-5; JAPAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; TH2 CELLS; UP-REGULATION;

EID: 3042753839     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2004.04.012     Document Type: Article

References (36)

1. Steinman L., Miller A., Bernard C.C., Oksenberg J.R. The epigenetics of multiple sclerosis: clues to etiology and a rationale for immune therapy. Annu. Rev. Neurosci. 17:1994;247-265
2. Martino G., Hartung H.P. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr. Opin. Neurol. 12:1999;309-321
3. Yong V.W., Chabot S., Stuve O., Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 51:1998;682-689
4. Dayal A.S., Jensen M.A., Lledo A., Arnason B.G.W. Interferon-gamma- secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology. 45:1995;2173-2177
5. Khan O.A., Hebel J.R. Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing-remitting multiple sclerosis. Ann. Neurol. 44:1998;138-139
6. Furlan R., Bergami A., Lang R., Brambilla E., Franciotta D., Martinelli V., et al. Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J. Neuroimmunol. 111:2000;86-92
7. Karp C.L., van Boxel-Dezaire A.H., Byrnes A.A., Nagelkerken L. Interferon-β in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10? Curr. Opin. Neurol. 14:2001;361-368
8. Kira J., Kanai T., Nishimura Y., Yamasaki K., Matsushita S., Kawano Y., et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann. Neurol. 40:1996;569-574
9. Yamasaki K., Horiuchi I., Minohara M., Kawano Y., Ohyagi Y., Yamada T., et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain. 122:1999;1689-1696
10. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50:2001;121-127
11. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452
12. Ochi H., Wu X.M., Osoegawa M., Horiuchi I., Minohara M., Murai H., et al. Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis. J. Neuroimmunol. 119:2001;297-305
13. Wandinger K.P., Sturzebecher C.S., Bielekova B., Detore G., Rosenwald A., Staudt L.M., et al. Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 50:2001;349-357
14. Gniadek P., Aktas O., Wandinger K.-P., Bellmann-Strobl J., Wengert O., Weber A., et al. Systemic IFN-β treatment induces apoptosis of peripheral immune cells in MS patients. J. Neuroimmunol. 137:2003;187-196
15. Ahn J., Feng X., Patel N., Dhawan N., Reder A.T. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis. Front. Biosci. 9:2004;1547-1555
16. Neumann H., Medana I.M., Bauer J., Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 25:2002;313-319
17. Ochi H., Osoegawa M., Wu X.M., Minohara M., Horiuchi I., Murai H., et al. Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. J. Neurol. Sci. 201:2002;45-51
18. Genain C.P., Abel K., Belmar N., Villinger F., Rosenberg D.P., Linington C., et al. Late complications of immune deviation therapy in a nonhuman primate. Science. 274:1996;2054-2057
19. Lafaille J.J., van de Keere F., Hsu A.L., Baron J.L., Haas W., Raine C.S., et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 186:1997;307-312
20. de Vries J.E. Molecular and biological characteristics of interleukin-13. Chem. Immunol. 63:1996;204-218
21. de la Barrera S., Finiasz M., Fink S., Ilarregui J., Alemán M., Olivares L., et al. NK cells modulate the cytotoxic activity generated by Mycobacterium leprae-hsp65 in leprosy patients: role of IL-18 and IL-13. Clin. Exp. Immunol. 135:2004;105-113
22. Zhang B., Yamamura T., Kondo T., Fujiwara M., Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186:1997;1677-1687
23. Baxter A.G., Smyth M.J. The role of NK cells in autoimmune disease. Autoimmunity. 35:2002;1-14
24. Kastrukoff L.F., Lau A., Wee R., Zecchini D., White R., Paty D.W. Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J. Neuroimmunol. 145:2003;103-114
25. Zurawski G., de Vries J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today. 15:1994;19-26
26. Cash E., Minty A., Ferrara P., Caput D., Fradelizi D., Rott O. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J. Immunol. 153:1994;4258-4267
27. Szczepanik A.M., Funes S., Petko W., Ringheim G.E. IL-4, IL-10 and IL-13 modulate A beta(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol. 113:2001;49-62
28. Sironi M., Sciacca F.L., Matteucci C., Conni M., Vecchi A., Bernasconi S., et al. Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. Blood. 84:1994;1913-1921
29. Bochner B.S., Klunk D.A., Sterbinsky S.A., Coffman R.L., Schleimer R.P. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J. Immunol. 154:1995;799-803
30. Zettl U.K., Mix E., Zielasek J., Stangel M., Hartung H.P., Gold R. Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell. Immunol. 178:1997;1-8
31. Bogdan C. The multiplex function of nitric oxide in (auto)immunity. J. Exp. Med. 187:1998;1361-1365
32. Willenborg D.O., Fordham S.A., Staykova M.A., Ramshaw I.A., Cowden W.B. IFN-γ is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J. Immunol. 163:1999;5278-5286
33. van der Veen R.C., Dietlin T.A., Dixon Gray J., Gilmore W. Macrophage-derived nitric oxide inhibits the proliferation of activated T helper cells and is induced during antigenic stimulation of resting T cells. Cell. Immunol. 199:2000;43-49
34. Nakashima I., Fujihara K., Misu T., Fujimori J., Sato S., Takase S., et al. A comparative study of Japanese multiple sclerosis patients with and without oligoclonal IgG bands. Mult. Scler. 8:2002;459-462
35. Horiuchi I., Kawano Y., Yamasaki K., Minohara M., Furue M., Taniwaki T., et al. Th1 dominance in HAM/TSP and the optico-spinal form of multiple sclerosis versus Th2 dominance in mite antigen-specific IgE myelitis. J. Neurol. Sci. 172:2000;17-24
36. Wu X.M., Osoegawa M., Yamasaki K., Kawano Y., Ochi H., Horiuchi I., et al. Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperIgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets. J. Neurol. Sci. 177:2000;24-31